BASF has launched a new synthetic peptide for skin care that aligns with the trend for slow aging. Inspired by the natural regenerative process of the skin, and based on a naturally occurring human biopeptide, Pepsensyal (INCI: Mannitol (and) Acetyl shTetrapeptide-1 (and) Lauroyl sh-Tetrapeptide-1) has been clinically proven to reduce and delay the first visible signs of aging, the company reports. The ingredient is additionally free of preservatives and 99% of natural origin.
Clinical Skin Smoothing, Resurfacing, Redensifying Testing
In a double-blind, randomized, split-face clinical trial of 32 women (44 to 64 years old), Pepsensyal at 0.2% was tested against a placebo product.
According to BASF, after just 14 days of product application:
- Subjects' crow's feet appeared smoother, with an 11% decrease in average roughness and a 14% decrease in maximum relief amplitude; and
- Skin isotropy increased by 15%, indicating a skin resurfacing effect.
Furthermore, Pepsensyal was proven to replenish the skin from the inside. After 28 days of product application, the skin had re-densified, with a 21% increase in the echogenic surface area of the dermis. Extensive in vitro testing additionally confirmed the ingredient's ability to support skin regeneration, helping to slow the visible signs of skin aging.
Embracing the Healthy, Slow Aging Mindset
The new ingredient was reportedly developed in response to the slow-aging trend, which reflects a shift in consumer attitudes about aging. Rather than fighting the natural aging process, consumers are increasingly focused on healthy aging through a holistic, preventative approach to skin care.
